{"DataElement":{"publicId":"7425484","version":"1","preferredName":"Bridge Therapy Administered Bridge Therapy Name","preferredDefinition":"The name of the bridge therapy that was administered.","longName":"PT_RCV_BRD_TX","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7433837","version":"1","preferredName":"Bridge Therapy Administered","preferredDefinition":"Therapy intended to transition a patient from one therapy or medication to another or maintain their health or status until they are a candidate for a therapy or have decided on a therapy._The act of having given something (e.g., a medication or test).","longName":"7433835v1.0:2233610v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7433835","version":"1","preferredName":"Bridge Therapy","preferredDefinition":"Therapy intended to transition a patient from one therapy or medication to another or maintain their health or status until they are a candidate for a therapy or have decided on a therapy.","longName":"C174554","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bridge Therapy","conceptCode":"C174554","definition":"Therapy intended to transition a patient from one therapy or medication to another or maintain their health or status until they are a candidate for a therapy or have decided on a therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0017AA0-2364-2210-E053-4EBD850A9612","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0017AA0-2372-2210-E053-4EBD850A9612","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"LAMEMIL","dateModified":"2021-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7412703","version":"1","preferredName":"Bridge Therapy Name","preferredDefinition":"Therapy intended to transition a patient from one therapy or medication to another or maintain their health or status until they are a candidate for a therapy or have decided on a therapy._The words or language units by which a thing is known.","longName":"7412703v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Dinutuximab + irinotecan and temozolomide","valueDescription":"Dinutuximab/Irinotecan/Temozolomide Regimen","ValueMeaning":{"publicId":"7437727","version":"1","preferredName":"Dinutuximab/Irinotecan/Temozolomide Regimen","longName":"7437727","preferredDefinition":"A regimen consisting of dinutuximab, irinotecan and temozolomide that can potentially be used for the treatment of neuroblastoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dinutuximab/Irinotecan/Temozolomide Regimen","conceptCode":"C174559","definition":"A regimen consisting of dinutuximab, irinotecan and temozolomide that can potentially be used for the treatment of neuroblastoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B027E21B-B5CC-440A-E053-4EBD850ADFC7","latestVersionIndicator":"Yes","beginDate":"2020-09-25","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-25","modifiedBy":"ONEDATA","dateModified":"2020-09-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B027E21B-B5E5-440A-E053-4EBD850ADFC7","beginDate":"2020-09-25","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-25","modifiedBy":"ONEDATA","dateModified":"2020-09-25","deletedIndicator":"No"},{"value":"Dinutuximab + other chemotherapy","valueDescription":"Dinutuximab And Other Chemotherapy","ValueMeaning":{"publicId":"7433873","version":"1","preferredName":"Dinutuximab And Other Chemotherapy","longName":"7433873","preferredDefinition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A chemotherapy other than the one specified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dinutuximab","conceptCode":"C1570","definition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other Chemotherapy","conceptCode":"C174557","definition":"A chemotherapy other than the one specified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B004B0D0-6A77-1470-E053-4EBD850A48C2","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B004B0D0-6A90-1470-E053-4EBD850A48C2","beginDate":"2020-09-03","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","deletedIndicator":"No"},{"value":"Other anti-GD2 therapy + irinotecan and temozolomide","valueDescription":"Other Anti-GD2 Therapy And Irinotecan/Temozolomide","ValueMeaning":{"publicId":"7433875","version":"1","preferredName":"Other Anti-GD2 Therapy And Irinotecan/Temozolomide","longName":"7433875v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned._Any therapy that specifically targets the tumor-associated antigen (TAA) disialoganglioside GD2._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A regimen consisting of irinotecan and temozolomide that can be used for the treatment of Ewing sarcoma or mesenchymal chondrosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Anti-GD2 Therapy","conceptCode":"C174558","definition":"Any therapy that specifically targets the tumor-associated antigen (TAA) disialoganglioside GD2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Irinotecan/Temozolomide Regimen","conceptCode":"C11820","definition":"A regimen consisting of irinotecan and temozolomide that can be used for the treatment of Ewing sarcoma or mesenchymal chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B004B0D0-6AA0-1470-E053-4EBD850A48C2","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"KUMMEROA","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B004B0D0-6AB9-1470-E053-4EBD850A48C2","beginDate":"2020-09-03","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","deletedIndicator":"No"},{"value":"Other anti-GD2 therapy + other chemotherapy","valueDescription":"Other Anti-GD2 Therapy And Other Chemotherapy","ValueMeaning":{"publicId":"7433876","version":"1","preferredName":"Other Anti-GD2 Therapy And Other Chemotherapy","longName":"7433876","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any therapy that specifically targets the tumor-associated antigen (TAA) disialoganglioside GD2.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A chemotherapy other than the one specified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Anti-GD2 Therapy","conceptCode":"C174558","definition":"Any therapy that specifically targets the tumor-associated antigen (TAA) disialoganglioside GD2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other Chemotherapy","conceptCode":"C174557","definition":"A chemotherapy other than the one specified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B004B0D0-6AC8-1470-E053-4EBD850A48C2","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B004B0D0-6AE1-1470-E053-4EBD850A48C2","beginDate":"2020-09-03","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","deletedIndicator":"No"},{"value":"Other chemotherapy","valueDescription":"Other Chemotherapy","ValueMeaning":{"publicId":"7433877","version":"1","preferredName":"Other Chemotherapy","longName":"7433877","preferredDefinition":"A chemotherapy other than the one specified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other Chemotherapy","conceptCode":"C174557","definition":"A chemotherapy other than the one specified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B004B0D0-6AED-1470-E053-4EBD850A48C2","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B004B0D0-6B06-1470-E053-4EBD850A48C2","beginDate":"2020-09-03","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","deletedIndicator":"No"},{"value":"Irinotecan and temozolomide","valueDescription":"Irinotecan/Temozolomide Regimen","ValueMeaning":{"publicId":"7437626","version":"1","preferredName":"Irinotecan/Temozolomide Regimen","longName":"7437626","preferredDefinition":"A regimen consisting of irinotecan and temozolomide that can be used for the treatment of Ewing sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Irinotecan/Temozolomide Regimen","conceptCode":"C11820","definition":"A regimen consisting of irinotecan and temozolomide that can be used for the treatment of Ewing sarcoma or mesenchymal chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B027CA9A-2E7A-4410-E053-4EBD850A2248","latestVersionIndicator":"Yes","beginDate":"2020-09-25","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-25","modifiedBy":"TAYLORT","dateModified":"2020-09-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B027CA9A-2E93-4410-E053-4EBD850A2248","beginDate":"2020-09-25","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-25","modifiedBy":"ONEDATA","dateModified":"2020-09-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435016","version":"1","preferredName":"Chemotherapy Regimen","preferredDefinition":"Drug therapy using two or more drugs given together or separately for a combined effect.","longName":"C12218","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B9F7-9264-25C9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7433872","version":"1","preferredName":"Bridge Therapy Name","preferredDefinition":"Therapy intended to transition a patient from one therapy or medication to another or maintain their health or status until they are a candidate for a therapy or have decided on a therapy.:The words or language units by which a thing is known.","longName":"C174554:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bridge Therapy","conceptCode":"C174554","definition":"Therapy intended to transition a patient from one therapy or medication to another or maintain their health or status until they are a candidate for a therapy or have decided on a therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0048CD3-F794-780D-E053-4EBD850AC31F","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6F0AB1-6089-2C2D-E053-4EBD850AF545","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2023-08-08","changeDescription":"Retired as part of draft content review.","administrativeNotes":"2023.8.8 Updated PVs def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"What bridging therapy did the","type":"Preferred Question Text","description":"What bridging therapy did the patient receive?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF779B01-1CD9-36EA-E053-4EBD850AAFA8","latestVersionIndicator":"Yes","beginDate":"2020-09-16","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-16","modifiedBy":"KUMMEROA","dateModified":"2023-05-23","changeDescription":null,"administrativeNotes":"2023.5.23 Updated def. ak","unresolvedIssues":null,"deletedIndicator":"No"}}